Annual Report and Accounts 2012 - Scapa
Annual Report and Accounts 2012 - Scapa
Annual Report and Accounts 2012 - Scapa
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
24. Provisions continued<br />
During the year to March <strong>2012</strong> the Group have received an updated report from Gnarus Advisers LLC to reconfirm its estimates of<br />
Waycross’s total liability for asbestos claims. The report reconfirmed that the provision recognised is still within the ranges predicted<br />
by the model. Sensitivities were applied to the model to determine the impact of changes to the key assumptions as noted below.<br />
The results indicated that the provision recognised is within the sensitised range. The key assumptions made in assessing the<br />
appropriate level of the provisions were as follows:<br />
– the number of people likely to have been exposed to Waycross/SDFI’s products – almost exclusively paper mill workers who were<br />
in active employment prior to 1980;<br />
– the rate of claim filing (also known as ‘propensity to sue’);<br />
– the rate of successful dismissal of claims filed;<br />
– the average amount to pay in respect of successful claims;<br />
– Waycross’s pending cases by type of disease claimed; <strong>and</strong><br />
– the future trend of legal costs<br />
The first assumption is very favourable for <strong>Scapa</strong>. The products were sold to <strong>and</strong> used exclusively in a very narrow <strong>and</strong> well defined<br />
set of circumstances. <strong>Scapa</strong> also has a full record of the customers, locations <strong>and</strong> dates of sales of the product in question – creating<br />
a very high evidential hurdle.<br />
The provision is discounted using a risk free rate of 3.35%; the unwind of the discount is applied to both the asset <strong>and</strong> the liability. The<br />
provision <strong>and</strong> receivable are held in US Dollars <strong>and</strong> converted at the year end exchange rate. The provision covers the time horizon to<br />
2053 which is the date when the Nicholson model predicts the last incidence of mesothelioma from any source at all in the USA.<br />
As in any long-term projection of this nature (41 year estimation period) there remains significant uncertainty associated with the future<br />
level of asbestos claims <strong>and</strong> the costs arising out of related litigation. There can be no guarantee that the assumptions used to<br />
estimate the provision will result in an accurate prediction of the actual costs that may be incurred <strong>and</strong>, as a result, the provision may<br />
be subject to potentially material revision from time to time if new information becomes available as a result of future events. However<br />
the updated results support the carrying of the liability <strong>and</strong> it is the Board opinion that the liability on the Balance Sheet at 31 March<br />
<strong>2012</strong> is appropriate, with the only changes being for foreign exchange movements <strong>and</strong> discount unwind.<br />
Product liability insurance asset<br />
Based on work performed by Dickstein Shapiro LLP, a prominent Washington DC law firm with expertise in the field of evaluating<br />
insurance coverage <strong>and</strong> the likelihood of recovery for asbestos-related claims, the Group has established the existence of insurance<br />
coverage to a level of certainty sufficient to recognise an insurance asset equal to the provision.<br />
It should be noted that there is a residual level of uncertainty around any insurance policy until such time it is actually drawn down<br />
upon <strong>and</strong> therefore the actual value of all accessible insurance may differ from the evaluation above. Given that the value of insurance<br />
policies is significantly in excess of any reasonable range of claims outcomes, the Board’s view is that this will not lead to any material<br />
financial impact on <strong>Scapa</strong>. In addition, the Board is of the view that any potential asbestos liabilities are ring-fenced within the nontrading<br />
sub-group of the North American business. This view is based on the principle of American law that a shareholder (including<br />
a parent corporation) is generally not liable for a separate legal entity’s obligations.<br />
Asbestos litigation costs<br />
Under the terms of a cost-sharing agreement entered into in 1996 the Group’s primary insurance carriers provided 50% of the<br />
defence costs associated with the asbestos-related claims. This share was renegotiated to 75% with effect from 1 April 2006.<br />
The litigation provision of £5.5m (2011: £5.7m) represents <strong>Scapa</strong>’s forecast share of defence costs over the lifetime of this issue<br />
<strong>and</strong> is consistent with the basis of calculation of the indemnity provision.<br />
Reorganisation <strong>and</strong> leasehold commitments<br />
The £2.5m (2011: £3.0m) reorganisation provision relates to dilapidations for leasehold property of £1.3m (2011: £0.9m), £0.7m<br />
(2011: £0.7m) for a l<strong>and</strong> value guarantee related to the Megolon disposal in 2007 <strong>and</strong> £0.5m (2011: £1.0m) in relation to<br />
reorganisation costs.<br />
Whilst the timing of the economic benefits relating to the non-current provisions cannot be ascertained with any degree of<br />
certainty, the leasehold commitments are expected to take place within the next 1-2 years.<br />
Environmental provisions<br />
Environmental provisions relate to expected costs required to clean up environmental contamination of a number of sites in both<br />
Europe of £0.2m (2011: £0.3m) <strong>and</strong> North America of £0.2m (2011: £0.3m). The Group expects the majority of the spend against<br />
the environmental provisions to be incurred over the next three years.<br />
<strong>Scapa</strong> Group plc <strong>Annual</strong> <strong>Report</strong> <strong>and</strong> <strong>Accounts</strong> <strong>2012</strong> 63<br />
Overview Business Review<br />
Governance<br />
Financial Statements